Launch of advanced assay kits and reagents is augmenting the growth of autoimmune disease diagnosis market

calendar_today 26 January, 2022 person_outline Growth Plus Reports

Autoimmune Disease Diagnosis Market by Product (Instruments and Consumables & Assay Kits), Type (Localized Autoimmune Disease Diagnostics, Systemic Autoimmune Disease Diagnostics), Test Type (Routine Laboratory Tests, Autoantibodies & Immunologic Test, and Inflammatory Markers)–Global Outlook & Forecast 2021-2031

According to the deep-dive market assessment study conducted by Growth+ Reports, the global autoimmune disease diagnosis market was pegged at ~US$ 3.95 billion in 2020. The market is expected to witness a CAGR of ~8.6% from 2021 to 2031.

Factors contributing to the growth of autoimmune disease diagnosis market include the rising incidence of autoimmune diseases; growing awareness about these diseases and the available diagnostic tests; and frequent launches of new and advanced assay kits and reagents. However, high capital investments for setting a diagnostic laboratory and dearth of skilled professionals to conduct these tests are some of the factors hindering the autoimmune disease diagnosis market growth to a certain extent.

The rising prevalance of autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus is one of the major factors boosting the growth of this market. According to the National Stem Cell Foundation, autoimmune diseases are the third most common cause of chronic illness in the U.S. Around 4% of the world’s population is affected by one of more than 80 different autoimmune diseases, the most common of these include type 1 diabetes, rheumatoid arthritis, lupus, Crohn’s disease, multiple sclerosis, psoriasis, and scleroderma.

Moreover, players in the market are focused on developing and launching new assay kits for diagnosis of various types of autoimmune diseases. For instance, in September 2020, Progentec launched a novel blood test that can assess the likelihood of a systemic lupus erythematosus (SLE) patient experiencing an immunologic disease flare in the ensuing 12 weeks. Therefore, such new product launches are playing a pivotal role in propelling the growth of autoimmune disease diagnosis market growth.

However, dearth of skilled professionals is one of the factors restraining the growth of this market to a certain extent. Moreover, limitations of these tests such as the variability of autoantibody results, the heterogeneity of testing, and incorrect diagnosis are some of the other concerns.

Regionally, Asia Pacific region is expected to grow at a higher CAGR during the forecast period. The rising prevalance of autoimmune disease and increasing awareness among the population in this region are key factors fueling the market growth. Moreover, the presence large population base with unmet clinical needs and the rising government spending to develop healthcare infrastructure are some of the other factors propelling the autoimmune disease diagnosis market growth in this region.

Some of the prominent players operating in the global autoimmune disease diagnosis market include Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, Abbott, Trinity Biotech Plc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., bioMérieux SA, Euroimmun Medizinische Labordiagnostika AG (a PerkinElmer company), and Inova Diagnostics, Inc., among others.

awards awards key differentiators

Reach Us

Web –

// // //